ATHE News and Press, Alterity Therapeutics Limited From 01/06/23

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology co...

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum PR Newswire MELBOURNE , Australia and SAN FRANCISCO , Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the C...

Alterity Therapeutics ( NASDAQ: ATHE ) stock rose ~9% on Thursday after the company said that a new composition of matter patent was allowed by the U.S. Patent and Trademark Office (USPTO). The company said the patent covers more than 100 novel compounds targeting neurode...

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office PR Newswire - Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com It’s time to check out the biggest pre-market stock movers that traders will want to know about on Monday! Moving stocks this morning are acquisition talks, delisting noti...

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (...

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report PR Newswire First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand , trial opens in Europe and Australia Approval of Investigational New Drug application by FDA to bring the Phase 2 clini...

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutic...

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy PR Newswire Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia ...

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders PR Newswire - Wearable sensors strongly correlated with clinical scales on motor impa...